These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33112842)

  • 1. HIF2α supports pro-metastatic behavior in pheochromocytomas/paragangliomas.
    Bechmann N; Moskopp ML; Ullrich M; Calsina B; Wallace PW; Richter S; Friedemann M; Langton K; Fliedner SMJ; Timmers HJLM; Nölting S; Beuschlein F; Fassnacht M; Prejbisz A; Pacak K; Ghayee HK; Bornstein SR; Dieterich P; Pietzsch J; Wielockx B; Robledo M; Qin N; Eisenhofer G
    Endocr Relat Cancer; 2020 Nov; 27(11):625-640. PubMed ID: 33112842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposing effects of HIF1α and HIF2α on chromaffin cell phenotypic features and tumor cell proliferation: Insights from MYC-associated factor X.
    Qin N; de Cubas AA; Garcia-Martin R; Richter S; Peitzsch M; Menschikowski M; Lenders JW; Timmers HJ; Mannelli M; Opocher G; Economopoulou M; Siegert G; Chavakis T; Pacak K; Robledo M; Eisenhofer G
    Int J Cancer; 2014 Nov; 135(9):2054-64. PubMed ID: 24676840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-inducible Factor 2α: A Key Player in Tumorigenesis and Metastasis of Pheochromocytoma and Paraganglioma?
    Bechmann N; Eisenhofer G
    Exp Clin Endocrinol Diabetes; 2022 May; 130(5):282-289. PubMed ID: 34320663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas.
    Toledo RA; Qin Y; Srikantan S; Morales NP; Li Q; Deng Y; Kim SW; Pereira MA; Toledo SP; Su X; Aguiar RC; Dahia PL
    Endocr Relat Cancer; 2013 Jun; 20(3):349-59. PubMed ID: 23533246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
    Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
    J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
    Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Somatic HIF2α Mutation-Induced Multiple and Recurrent Pheochromocytoma/Paraganglioma with Polycythemia: Clinical Study with Literature Review.
    Liu Q; Wang Y; Tong D; Liu G; Yuan W; Zhang J; Ye J; Zhang Y; Yuan G; Feng Q; Zhang D; Jiang J
    Endocr Pathol; 2017 Mar; 28(1):75-82. PubMed ID: 28116635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
    Toledo RA
    Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype.
    Celada L; Cubiella T; San-Juan-Guardado J; Gutiérrez G; Beiguela B; Rodriguez R; Poch M; Astudillo A; Grijalba A; Sánchez-Sobrino P; Tous M; Navarro E; Serrano T; Paja M; Valdés N; Chiara MD
    J Pathol; 2023 Jan; 259(1):103-114. PubMed ID: 36314599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
    Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma.
    Karakaya S; Gunnesson L; Elias E; Martos-Salvo P; Robledo M; Nilsson O; Wängberg B; Abel F; Påhlman S; Muth A; Mohlin S
    Sci Rep; 2023 Jul; 13(1):11588. PubMed ID: 37463949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
    Pamporaki C; Hamplova B; Peitzsch M; Prejbisz A; Beuschlein F; Timmers HJLM; Fassnacht M; Klink B; Lodish M; Stratakis CA; Huebner A; Fliedner S; Robledo M; Sinnott RO; Januszewicz A; Pacak K; Eisenhofer G
    J Clin Endocrinol Metab; 2017 Apr; 102(4):1122-1132. PubMed ID: 28324046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pseudohypoxic pheochromocytomas and paragangliomas dominate in children.
    Redlich A; Pamporaki C; Lessel L; Frühwald MC; Vorwerk P; Kuhlen M
    Pediatr Blood Cancer; 2021 Jul; 68(7):e28981. PubMed ID: 33682326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EPAS1-related pheochromocytoma/paraganglioma.
    Alzahrani AS; Alswailem M; Buffet A; Alghamdi B; Alobaid L; Alsagheir O; Al-Hindi H; Pacak K
    Endocr Relat Cancer; 2024 Aug; 31(8):. PubMed ID: 38767322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Pheochromocytoma Cells with Recurrent Cycles of Hypoxia: A New Pseudohypoxic In Vitro Model.
    Helm J; Drukewitz S; Poser I; Richter S; Friedemann M; William D; Mohr H; Nölting S; Robledo M; Bornstein SR; Eisenhofer G; Bechmann N
    Cells; 2022 Feb; 11(3):. PubMed ID: 35159368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic and Molecular Biomarkers in Aggressive Pheochromocytomas and Paragangliomas.
    Torresan F; Iacobone C; Giorgino F; Iacobone M
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
    Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
    Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas.
    Remacha L; Pirman D; Mahoney CE; Coloma J; Calsina B; Currás-Freixes M; Letón R; Torres-Pérez R; Richter S; Pita G; Herráez B; Cianchetta G; Honrado E; Maestre L; Urioste M; Aller J; García-Uriarte Ó; Gálvez MÁ; Luque RM; Lahera M; Moreno-Rengel C; Eisenhofer G; Montero-Conde C; Rodríguez-Antona C; Llorca Ó; Smolen GA; Robledo M; Cascón A
    Am J Hum Genet; 2019 Apr; 104(4):651-664. PubMed ID: 30929736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
    Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.